Xu Jing-Jing, Xu Feng, Wang Wei, Zhang Yi-Fan, Hao Bei-Quan, Shang Ming-Ying, Liu Guang-Xue, Li Yao-Li, Yang Shu-Bin, Wang Xuan, Cai Shao-Qing
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
Front Pharmacol. 2022 Mar 4;13:842839. doi: 10.3389/fphar.2022.842839. eCollection 2022.
In the clinical practice of traditional Chinese medicine, toxic heat and blood stasis syndrome (THBSS) is a common syndrome observed in various critical diseases. Paeoniae Radix Rubra (PRR) has known therapeutic effects on THBSS. However, its pharmacodynamic mechanisms and effective substances in the treatment of THBSS still need further elucidation. Our previous study indicated that THBSS had three stages of progression, and the abnormal biochemical indices of each stage were different. Therefore, this study aimed to elucidate the pharmacodynamic mechanisms and effective substances of PRR for the treatment of THBSS with a stage-oriented strategy. Specifically, research was performed separately in two stable stages of THBSS: the excessive heat and little blood stasis (EHLBS) and blood stasis (BS) stages. THBSS model rats, at different time periods after syndrome initiation (first 5 h for EHLBS and 24 h later for BS), were used to conduct the two-stage investigation. Targeted metabonomics analysis was performed to elucidate the pharmacodynamic mechanisms of PRR in the treatment of EHLBS or BS. Based on the relationship between the individual differences in blood drug concentrations and pharmacodynamic effects, partial least squares regression analysis was employed to screen for the effective substances from the original constituents and metabolites of PRR. We found that PRR could upregulate primary bile acid biosynthesis, glycerophospholipid metabolism, ether lipid metabolism, and five amino acid metabolic pathways (e.g., arginine and proline metabolism) to treat EHLBS. Meanwhile, PRR alleviated BS by upregulating primary bile acid biosynthesis and downregulating glycerophospholipid metabolism. But PRR had no obvious effects on ether lipid metabolism and amino acid metabolism in this stage. In total, 17 and 9 potential effective substances were found in the EHLBS and BS stages, respectively, among which there were only five common compounds between the two stages. To our knowledge, sixteen compounds were regarded as potential effective substances of PRR for the first time. Therefore, the pharmacodynamic mechanisms and effective substances of PRR in the treatment of EHLBS and BS were partly different. Overall, this stage-oriented strategy provides a new way to study the pharmacodynamic mechanisms and effective substances of traditional Chinese drugs.
在中医临床实践中,热毒血瘀证是多种危急重症中常见的证候。赤芍对热毒血瘀证具有确切的治疗作用。然而,其治疗热毒血瘀证的药效机制及有效物质仍需进一步阐明。我们前期研究表明,热毒血瘀证有三个进展阶段,各阶段的异常生化指标有所不同。因此,本研究旨在采用分期论治策略阐明赤芍治疗热毒血瘀证的药效机制及有效物质。具体而言,在热毒血瘀证的两个稳定阶段分别开展研究:即热盛瘀轻症和血瘀证阶段。采用热毒血瘀证模型大鼠,在证候初起后的不同时间段(热盛瘀轻症为起证后5小时,血瘀证为起证后24小时)进行两阶段研究。运用靶向代谢组学分析阐明赤芍治疗热盛瘀轻症或血瘀证的药效机制。基于血药浓度个体差异与药效作用的关系,采用偏最小二乘回归分析从赤芍的原成分及代谢产物中筛选有效物质。我们发现,赤芍可通过上调初级胆汁酸生物合成、甘油磷脂代谢、醚脂代谢及五条氨基酸代谢途径(如精氨酸和脯氨酸代谢)来治疗热盛瘀轻症。同时,赤芍通过上调初级胆汁酸生物合成及下调甘油磷脂代谢来缓解血瘀证。但赤芍在此阶段对醚脂代谢和氨基酸代谢无明显影响。在热盛瘀轻症和血瘀证阶段分别发现了17种和9种潜在有效物质,其中两阶段仅有5种共同化合物。据我们所知,有16种化合物首次被视为赤芍的潜在有效物质。因此,赤芍治疗热盛瘀轻症和血瘀证的药效机制及有效物质存在部分差异。总体而言,这种分期论治策略为研究中药的药效机制及有效物质提供了新途径。